Cardiol Therapeutics Inc. (CRDL) intrinsic value & 10-year financials
Cardiol Therapeutics Inc. (CRDL) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2023)
- —
- ROIC (10-yr avg)
- -92.2%
- Free cash flow (FY2023)
- -CAD 25.2M
CRDL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2023 | — | -CAD 28.1M | -CAD 0.44 | -CAD 25.2M | — | -69.9% |
| FY2022 | — | -CAD 30.9M | -CAD 0.49 | -CAD 27.3M | — | -64.4% |
| FY2021 | CAD 78.8K | -CAD 31.6M | -CAD 0.73 | -CAD 23.6M | -49091.9% | -86.4% |
| FY2020 | — | -CAD 20.6M | -CAD 0.69 | -CAD 9.2M | — | -148.1% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in CAD.
Executive summary
Cardiol Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Cardiol Therapeutics Inc. 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
Cardiol Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Cardiol Therapeutics Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.